The 10 most recent market catalysts affecting $TLSA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Tiziana Life Sciences shares are trading higher after the company announced the signing of a a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating a combination of the proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone.
This headline represents a significant corporate catalyst for Tiziana Life Sciences. The Memorandum of Understanding for a clinical trial evaluating foralumab in combination with e…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Tiziana Life Sciences Announces MOU With King Abdullah International Medical Research Center And Foundation For Neurologic Diseases For Trial Of Intranasal Foralumab With Anti-CD20 Therapy In Relapsing-Remitting MS
This MOU is a significant positive catalyst for Tiziana Life Sciences (TLSA) as it expands the clinical development of their lead asset, Foralumab, into a combination therapy for R…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 65
Tiziana Life Sciences shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $7 price target.
The initiation of coverage by a reputable firm like BTIG with a 'Buy' rating and a significant price target acts as a strong corporate catalyst for Tiziana Life Sciences. This prov…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 65
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiated coverage on Tiziana Life Sciences (TLSA) with a 'Buy' rating and a $7 price target. This event is significant for TLSA as new analyst coverage…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
Tiziana Life Sciences is announcing the presentation of a poster at ALS Nexus 2026, detailing their Phase 2a BANYAN trial for intranasal foralumab in ALS. This is a positive develo…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 667,000 Common Shares At $1.00 Per Share, Raising Total Holding To 4,472,261 Shares
The CEO's substantial purchase of Tiziana Life Sciences shares at a fixed price of $1.00, significantly increasing his total holding, is a strong vote of confidence from an insider…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 85
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
This headline represents a significant positive catalyst for Tiziana Life Sciences (TLSA). Positive early-stage clinical trial data, especially in a challenging disease like Multip…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity
Tiziana Life Sciences reported encouraging quantitative PET imaging results for its lead candidate, intranasal foralumab, in a Phase 2 clinical trial for Multiple System Atrophy (M…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 55
Tiziana Life Sciences shares are trading higher after the company announced its executive chairman bought 42,357 shares.
This headline indicates a corporate catalyst in the form of insider buying. The executive chairman's purchase of shares is generally viewed positively by the market as it suggests …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.